drugset / Trial / NCT01700049

Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

NCT01700049

Phase 2 Completed 28 enrolled Mayo Clinic Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study.

Timeline

Start
2013-01-14
Primary completion
2017-07-03
Completion
2018-07-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vismodegib Small molecule 150 mg Oral

Indications